Sigyn Therapeutics, Inc. (SIGY)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenues | - | - | - | - |
| Gross profit | - | - | - | - |
| Research and development | 7,482 | 8,842 | 206,161 | 240,429 |
| Marketing expenses | 8 | 176 | 114 | 8 |
| General and administrative | 412,023 | 487,041 | 564,683 | 324,868 |
| Stock based compensation | 50,000 | 50,000 | 37,500 | 37,500 |
| Total operating expenses | 469,513 | 546,059 | 808,458 | 602,805 |
| Loss from operations | -469,513 | -546,059 | -808,458 | -602,805 |
| Other income | 5,797 | - | - | - |
| Interest expense | 873 | 448 | 850 | 569 |
| Modification of warrants | 17,505 | - | 24,770 | - |
| Interest expense - original issuance costs | 81,017 | 94,353 | 99,126 | 142,272 |
| Interest expense - debt discount | 42,175 | 27,704 | 263,719 | 116,737 |
| Inducement of preferred shares | 845,901 | - | - | - |
| Total other expense | -981,674 | -122,505 | -388,465 | -259,578 |
| Loss before income taxes | -1,451,187 | -668,564 | -1,196,923 | -862,383 |
| Income taxes | - | - | - | - |
| Net loss | -1,451,187 | -668,564 | -1,196,923 | -862,383 |
| Net loss per share, basic | -0.9 | -0.42 | -0.94 | -0.7 |
| Net loss per share, diluted | -0.9 | -0.42 | -0.94 | -0.7 |
| Weighted average number of shares outstanding, basic | 1,605,377 | 1,605,377 | 1,268,795 | 1,238,085 |
| Weighted average number of shares outstanding, diluted | 1,605,377 | 1,605,377 | 1,268,795 | 1,238,085 |